Phase 1 Alzheimer's Disease Trial, Recruiting NCT07234942 Sponsor: Hoffmann-La Roche Condition: Alzheimer's Disease
Back to Alzheimers Disease

Phase 1 Alzheimer's Disease Trial, Recruiting

NCT07234942
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with either Alzheimer's disease dementia or mild memory and thinking problems (Mild Cognitive Impairment) that are believed to be caused by Alzheimer's disease, based on recognised medical guidelines.
  • You are willing and able to take part in all parts of the study, either on your own or with the help of a study partner (such as a family member or carer).
  • You can speak and understand the language used in the tests at the study location.
  • You have good enough vision and hearing to complete thinking and memory tests — glasses and hearing aids are allowed.
  • If you are already taking medication for Alzheimer's symptoms, you have been on a stable, unchanged dose for at least 8 weeks before joining the study.
  • You agree not to take part in any other research studies while this study is ongoing.

Who may not be able to join:

  • You have another medical condition (aside from Alzheimer's disease) that could affect your memory or thinking.
  • A brain scan (MRI) shows abnormalities that would make a lumbar puncture (spinal fluid test) unsafe for you.
  • You have other significant brain abnormalities that the study doctor considers a concern (confirm with trial site).
  • You have a history of schizophrenia, schizoaffective disorder, major depression, or bipolar disorder.
  • You have an unstable or poorly controlled condition affecting your heart, lungs, liver, kidneys, digestive system, hormones, or blood that could affect your safety or interfere with the study results.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Clinical Trials, Hoffmann-La Roche

Phone: 888-662-6728 (U.S. and Canada)

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Registry
ClinicalTrials.gov
Start date
27 January 2026
Est. completion
19 April 2028

Where this trial is recruiting

🇨🇦 Canada 🇳🇱 Netherlands 🇪🇸 Spain 🇸🇪 Sweden 🇬🇧 United Kingdom

Primary endpoints

Percentage of Participants with Adverse Events; Change From Baseline in Columbia-Suicide Severity Rating Scale (C-SSRS) Scores

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov